Skip to main content

RSV Antibody Treatment Effective For Babies

Medically reviewed by Carmen Pope, BPharm. Last updated on May 6, 2025.

By Dennis Thompson HealthDay Reporter

TUESDAY, May 6, 2025 -- Newborns can be effectively protected against respiratory syncytial virus (RSV) infection through the use of nirsevimab, a monoclonal antibody treatment, researchers report.

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in The Lancet Child & Adolescent Health.

The antibody treatment also reduced the risk of intensive care admissions by 81% and instances of lower respiratory tract infections by 75% in children younger than 1 year old, results show.

Nirsevimab also was more effective in preventing RSV-related hospitalizations in infants older than 3 months (81%) compared to those 3 months or younger (76%), researchers report.

“Our findings indicate that the benefits of nirsevimab observed in clinical trials are also evident in real-world settings, effectively reducing the burden of RSV disease in infants and, consequently, health-care use,” concluded the team led by senior researcher Seyed Moghadas, a professor of computational epidemiology and vaccine science with York University in Ontario, Canada.

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two methods. An expectant mother can pass on protection by getting an RSV vaccine while pregnant, or a newborn can be given antibody treatment to protect them against RSV.

To check the effectiveness of nirsevimab, researchers combined data from 27 studies conducted during the 2023-2024 RSV season across five countries — France, Italy Luxembourg, Spain and the United States.

Although the protection from the antibody treatment was high, researchers found that its effectiveness did vary by country.

The U.S. had higher effectiveness, with 93% of treated infants avoiding hospitalization, compared with 83% in Spain and 76% in France.

That might be because more babies who got the antibody treatment were at high risk of severe disease in the U.S., researchers said. The U.S. prioritized nirsevimab treatment for high-risk infants during the season under study, due to a limited supply of the antibody treatment.

“Our findings underscore the importance of infant immunization programs in alleviating the health and economic burden of RSV disease in the high-risk period following birth,” researchers concluded.

Sources

  • The Lancet, news release, May 1, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted May 2025

Read this next

COVID Boosters Might Not Be Updated For Next Season, FDA Commissioner Says

TUESDAY, May 6, 2025 -- The head of the U.S. Food and Drug Administration (FDA) reiterated Tuesday that the agency is applying a more skeptical approach to this year’s round...

U.S. Sees Most Child Flu Deaths Since 2009

MONDAY, May 5, 2025 — More U.S. children have died from the flu this season than in any year since the 2009 swine flu pandemic, according to a new federal report. So...

HHS, NIH Unveil Vaccine Initiative to Protect Against Future Pandemics

FRIDAY, May 2, 2025 -- The U.S. Department of Health and Human Services and the National Institutes of Health announced a new initiative called "Generation Gold Standard" to...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.